WILMINGTON, Del., March 08, 2017 -- Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Clayton Williams Energy, Inc. (“Clayton Williams Energy” or the “Company”).
If you currently own shares of Clayton Williams and want to receive additional information and protect your investments free of charge, please visit us at http://www.andrewsspringer.com/cases-investigations/clayton-williams-energy-class-action-investigation/ or contact Craig J. Springer, Esq. at [email protected], or call toll free at 1-800-423-6013. You may also follow us on LinkedIn – www.linkedin.com/company/andrews-&-springer-llc, Twitter – www.twitter.com/AndrewsSpringer or Facebook - www.facebook.com/AndrewsSpringer for future updates.
Andrews & Springer is a boutique securities class action law firm representing shareholders nationwide who are victims of securities fraud, breaches of fiduciary duty or corporate misconduct. Having formerly defended some of the largest financial institutions in the world, our founding members use their valuable knowledge, experience, and superior skill for the sole purpose of achieving positive results for investors. These traits are the hallmarks of our innovative approach to each case our Firm decides to prosecute. For more information please visit our website at www.andrewsspringer.com. This notice may constitute Attorney Advertising.
Contact: Craig J. Springer, Esq. [email protected] Toll Free: 1-800-423-6013


Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 



